Pitanium Limited Notified of Anticipated Delisting from The Nasdaq Stock Market
Get Alerts NDAQ Hot Sheet
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 1.2%
EPS Growth %: +14.1%
Join SI Premium – FREE
NEW YORK, July 07, 2026 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market (Nasdaq: NDAQ) announced today that it has notified Pitanium Limited (Nasdaq: PTNM) that its securities will be delisted from the Nasdaq Stock Market LLC on July 16, 2026, unless the company appeals to a Listing Qualifications Hearings Panel. The securities will remain halted, and unavailable to trade, until any appeal is resolved. Following removal from Nasdaq the securities may be eligible for trading in the over-the-counter market.
Following a temporary trading suspension in the Company’s securities by the U.S. Securities and Exchange Commission (https://www.sec.gov/files/litigation/suspensions/2025/34-104165-ts.pdf) Nasdaq halted trading in the Company’s ordinary shares on October 18, 2025. Nasdaq has now determined that it is appropriate to use its authority under IM-5101-4 to delist the Company’s securities from Nasdaq.
For news and additional information about the company, please review the companies’ public filings or contact the company directly.
For more information about The Nasdaq Stock Market, visit the Nasdaq Web site at http://www.nasdaq.com. Nasdaq’s rules governing the delisting of securities can be found in the Nasdaq Rule 5800 Series, available on the Nasdaq Web site: https://listingcenter.nasdaq.com/rulebook/nasdaq/rules/nasdaq-5800-series.
Source: Nasdaq, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Adani Green Energy (ADANIGR:IN) PT Raised to INR1,650 at Investec
- Northrim BanCorp to acquire PBCO Financial in $167M all-stock deal
- FDA accepts Revolution Medicines NDA for daraxonrasib in pancreatic cancer
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share